TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

SKYE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Faruqi & Faruqi, Llp
SKYE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

A securities class action has been filed against Skye Bioscience after the company announced that its drug nimacimab failed to meet primary endpoints in a Phase 2a clinical trial on October 6, 2025. The announcement revealed lower-than-expected drug exposure, causing the stock to plummet 60% from $4.75 to $1.90 per share. Investors who purchased securities between November 4, 2024 and October 3, 2025 are encouraged to contact the law firm, with a January 16, 2026 deadline to seek lead plaintiff status.

Insights
SFpD   positive

The company is proactively engaging with investors through a public presentation, demonstrating transparency and confidence in its business performance


SKYE   negative

The company failed to achieve primary endpoints in a Phase 2a clinical trial for its lead drug candidate nimacimab, revealed lower-than-expected drug exposure, and experienced a 60% stock price decline. These developments have triggered a federal securities class action lawsuit alleging false and misleading statements about the drug's effectiveness and commercial prospects.